Development and validation of a risk model with variables related to non-small cell lung cancer in patients with pulmonary nodules: a retrospective study

被引:0
|
作者
Liao, Zufang [1 ]
Zheng, Rongjiong [2 ]
Li, Ni [3 ]
Shao, Guofeng [3 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Ningbo 315041, Zhejiang, Peoples R China
[2] Ningbo Yinzhou 2 Hosp, Ningbo 315192, Zhejiang, Peoples R China
[3] Ningbo Univ, Dept Cardiothorac Surg, Li Huili Hosp, Xingning Rd 57, Ningbo 315041, Zhejiang, Peoples R China
关键词
NSCLC; Pulmonary nodules; Logistic; Variables; Model; GROUND-GLASS OPACITY; SOCIETY GUIDELINES; PROBABILITY; MANAGEMENT; BLOCKERS; TISSUE;
D O I
10.1186/s12885-023-11385-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLung cancer is a major global threat to public health for which a novel predictive nomogram is urgently needed. Non-small cell lung cancer (NSCLC) which accounts for the main port of lung cancer cases is attracting more and more people's attention.Patients and methodsHere, we designed a novel predictive nomogram using a design dataset consisting of 515 pulmonary nodules, with external validation being performed using a separate dataset consisting of 140 nodules and a separate dataset consisting of 237 nodules. The selection of significant variables for inclusion in this model was achieved using a least absolute shrinkage and selection operator (LASSO) logistic regression model, after which a corresponding nomogram was developed. C-index values, calibration plots, and decision curve analyses were used to gauge the discrimination, calibration, and clinical utility, respectively, of this predictive model. Validation was then performed with the internal bootstrapping validation and external cohorts.ResultsA predictive nomogram was successfully constructed incorporating hypertension status, plasma fibrinogen levels, blood urea nitrogen (BUN), density, ground-glass opacity (GGO), and pulmonary nodule size as significant variables associated with nodule status. This model exhibited good discriminative ability, with a C-index value of 0.765 (95% CI: 0.722-0.808), and was well-calibrated. In validation analyses, this model yielded C-index values of 0.892 (95% CI: 0.844-0.940) for external cohort and 0.853 (95% CI: 0.807-0.899) for external cohort 2. In the internal bootstrapping validation, C-index value could still reach 0.753. Decision curve analyses supported the clinical value of this predictive nomogram when used at a NSCLC possibility threshold of 18%.ConclusionThe nomogram constructed in this study, which incorporates hypertension status, plasma fibrinogen levels, BUN, density, GGO status, and pulmonary nodule size, was able to reliably predict NSCLC risk in this Chinese cohort of patients presenting with pulmonary nodules.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study
    Zou, Wei
    Xu, Neng-Luan
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2797 - 2804
  • [32] Development of a Survival Prognostic Model for Non-small Cell Lung Cancer
    Zhang, Yue-Hua
    Lu, Yuquan
    Lu, Hong
    Zhou, Yue-Min
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [33] Development and Validation of an ADRB2-based Prognostic Model for Non-Small Cell Lung Cancer
    Wang, T.
    Bu, S.
    Wang, X.
    Ge, H.
    Yang, C.
    Zheng, X.
    Liu, Y.
    Dong, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S443 - S444
  • [34] Adverse events related to nivolumab in non-small cell lung cancer (NSCLC): a retrospective observational study
    Sassier, M.
    Oulkhouir, Y.
    Gervais, R.
    Alexandre, J.
    Humbert, X.
    Coquerel, A.
    Fedrizzi, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 31 - 32
  • [35] A retrospective analysis of non-small cell lung cancer patients treated with nivolumab
    Akagi, Kazumasa
    Honda, Noritaka
    Umeyama, Yasuhiro
    Ogawara, Daiki
    Ikeda, Takaya
    Yamaguchi, Hiroyuki
    Kitazaki, Takeshi
    Nakatomi, Katsumi
    Fukuda, Minoru
    Mukae, Hiroshi
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] RETROSPECTIVE STUDY OF RADIOLOGICAL FINDINGS OF PULMONARY EMBOLISMS (PE) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Capelletto, E.
    Novello, S.
    Solitro, F.
    Focaraccio, L.
    Levra, M. Giaj
    Rapetti, S. G.
    Vavala, T.
    Menis, J.
    Veltri, A.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2012, 23 : 444 - 444
  • [37] Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer
    Cai, Yongsheng
    Dong, Honghong
    Li, Xinyang
    Liu, Yi
    Hu, Bin
    Li, Hui
    Miao, Jinbai
    Chen, Qirui
    CANCER MEDICINE, 2023, 12 (02): : 1217 - 1227
  • [38] Development of a Risk Score to Predict Postoperative Complications in Patients with Non-small Cell Lung Cancer
    Mallaev, M.
    Tsvetkov, N.
    Simmen, U.
    Bachmann, H.
    Koenig, D.
    Rothschild, S.
    Tamm, M.
    Hojski, A.
    Lardinois, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S592 - S592
  • [39] Risk factors for pulmonary infection in patients with non-small cell lung cancer: a Meta-analysis
    Chen, Jin
    Liu, Yu
    Cai, Hong
    Zheng, Wenfa
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [40] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
    Ivette F Emery
    Chiara Battelli
    Paul L Auclair
    Kathleen Carrier
    Daniel M Hayes
    BMC Cancer, 9